Ken is President and CEO at RayzeBio. Ken’s experience spans clinical medicine, basic science research, product development and global commercialization, venture capital, and entrepreneurship. Ken is also the co-founder and Chairman of the Board at Ablaze Pharmaceuticals, which is focused on radiopharmaceuticals development for the Greater China market. Prior to RayzeBio, he was President and CEO of Metacrine, Inc. where he led the organization from research to mid-stage clinical development and also positioned the company for an IPO. From 2010 to 2016, Ken was the co-founder and CEO of Ariosa Diagnostics (acquired by Roche) where he led the organization from early research to global commercialization of the Harmony Prenatal Test in over 100 countries. Ken also served as Executive Chairman of Omniome (acquired by Pacific Biosciences), a sequencing technology company, helping it mature from a research to product development company.
Prior to being an operator and entrepreneur, Ken worked as a venture capitalist at Venrock as well as consultant at McKinsey & Company. Ken trained in internal medicine at the University of California, San Francisco (UCSF) and specialized in gastroenterology and hepatology at the University of Washington along with a scientific research fellowship at the Fred Hutchinson Cancer Center. He earned his B.S. from Massachusetts Institute of Technology and M.D. from UCSF.